Article ; Online: Aldosterone in chronic kidney disease and renal outcomes.
2023 Volume 43, Issue 38, Page(s) 3781–3791
Abstract: Aims: Randomized controlled trials have demonstrated the efficacy of mineralocorticoid receptor (MR) antagonism in delaying chronic kidney disease (CKD) progression in diabetes; however, they have not investigated the role of aldosterone or whether ... ...
Abstract | Aims: Randomized controlled trials have demonstrated the efficacy of mineralocorticoid receptor (MR) antagonism in delaying chronic kidney disease (CKD) progression in diabetes; however, they have not investigated the role of aldosterone or whether these beneficial effects could be achieved in individuals without diabetes. Methods and results: The association between serum aldosterone concentrations and kidney disease progression was investigated among 3680 participants in the Chronic Renal Insufficiency Cohort. The primary outcome was CKD progression [defined as the composite of 50% decline in estimated glomerular filtration rate (eGFR) or end-stage kidney disease, whichever occurred first]. The associations between serum aldosterone and kidney disease outcomes were assessed using Cox proportional hazard models. At baseline, higher aldosterone concentrations were associated with a lower eGFR, lower serum potassium, greater urinary potassium, and protein excretion. Over a median follow-up of 9.6 years, 1412 participants developed CKD progression. In adjusted models, each doubling of serum aldosterone was associated with a 11% increased risk of CKD progression [hazard ratio (HR) 1.11, 95% confidence interval (CI) 1.04-1.18]. Individuals with the highest quartile of serum aldosterone had a 45% increased risk of CKD progression (HR 1.45, 95% CI 1.22-1.73) compared with the lowest quartile. The risk for CKD progression was similar regardless of whether patients had concomitant diabetes (P-interaction = 0.10). Conclusion: Higher serum aldosterone levels among individuals with CKD are independently associated with an increased risk for kidney disease progression, irrespective of concomitant diabetes. These findings provide mechanistic support for MR antagonists in delaying CKD progression and suggest that they may also have a role in those without diabetes. |
---|---|
MeSH term(s) | Aldosterone ; Diabetes Mellitus ; Disease Progression ; Glomerular Filtration Rate ; Humans ; Kidney ; Mineralocorticoid Receptor Antagonists/therapeutic use ; Potassium ; Receptors, Mineralocorticoid ; Renal Insufficiency, Chronic/complications ; Risk Factors |
Chemical Substances | Mineralocorticoid Receptor Antagonists ; Receptors, Mineralocorticoid ; Aldosterone (4964P6T9RB) ; Potassium (RWP5GA015D) |
Language | English |
Publishing date | 2023-02-06 |
Publishing country | England |
Document type | Journal Article |
ZDB-ID | 603098-1 |
ISSN | 1522-9645 ; 0195-668X |
ISSN (online) | 1522-9645 |
ISSN | 0195-668X |
DOI | 10.1093/eurheartj/ehac352 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1563: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 640: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.